PPARA and steatosis: The correlation analyses between improvement of CMH markers such as IR and hs-CRP and markers of hepatic health including steatosis, and histological MASH activity observed in this study point toward multidirectional interactions in disease biology that may add to the benefits of pan-PPAR agonist therapy.